Please login to the form below

Not currently logged in
Email:
Password:

InterMune

This page shows the latest InterMune news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Intercept's rare liver disease drug

FDA panel backs Intercept's rare liver disease drug

as candidates from Shire, Genfit, Galectin, Roche/InterMune and Takeda.

Latest news

  • Roche says Esbriet boosts survival in pulmonary fibrosis Roche says Esbriet boosts survival in pulmonary fibrosis

    The finding is a clinical first in IPF and is a massive boost for Esbriet (pirfenidone), which Roche acquired last year along with its original developer InterMune in an $8.3bn

  • Roche pharma sales strong for first half of 2015 Roche pharma sales strong for first half of 2015

    recently acquired with the purchase of US biotech InterMune - were also healthy, with Kadcyla up 65% to CHF362m and Esbriet CHF229m in its first six months under Roche. ... I am very encouraged by the strong uptake of our new medicine Esbriet, for

  • Data transparency in Europe Data transparency in Europe

    He pointed to recent lawsuits from AbbVie and InterMune against the EMA over its policy to publish data about its drugs Humira, for auto-inflammatory diseases (and the biggest-selling medicine

  • Takeda enlists GE's aid to tackle liver fibrosis epidemic Takeda enlists GE's aid to tackle liver fibrosis epidemic

    Meanwhile InterMune, which has been bought by Roche for $8bn, has said it has a pipeline of drugs with potential in liver and kidney fibrosis to go alongside Esbriet (pirfenidone), which

  • BMS takes option to buy fibrosis firm Galecto BMS takes option to buy fibrosis firm Galecto

    Idiopathic pulmonary fibrosis (IPF) is a debilitating and life-threatening condition that, until the approval of Roche/Intermune's Esbriet (pirfenidone) in Europe in 2011, had no approved drug treatments.

More from news
Approximately 4 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

  • Pharma deals during August 2014 Pharma deals during August 2014

    Instead came the news that Roche had beaten a host of companies including Sanofi, GSK, Actelion and Gilead in the acquisition of InterMune for $8.3bn ($74.00 a share, representing ... InterMune is also developing a pirfenidone analogue to treat specialty

  • Orphan indication? No easy access Orphan indication? No easy access

    Only the case of Intermune's idiopathic pulmonary fibrosis drug Esbriet (perfenidone) was the balance of benefit and risk to patients considered and a finding of 'no proven added benefit' was

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year. ... He played a large role in the launch of InterMune's flagship product, the lung-scarring drug

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics